Tonix Pharmaceuticals Holding Corp. · NASDAQ:TNXP

Tonix Pharmaceuticals — BIO and Solve M.E. Virtual Event (February 2023)

8 slides from Tonix Pharmaceuticals's conference presentation, Feb 21, 2023

  1. Slide 1: BIO and Solve M.E. Virtual Event

    BIO and Solve M.E. Virtual Event “Long Covid: What Will It Take To Accelerate Therapeutic Progress?” NASDAQ: TNXP Version P0413 February 21, 2023 (Doc 1170) © 2023 Tonix Pharmaceuticals Holding Corp.

  2. Slide 2: Cautionary Note on Forward-Looking Statements

    Cautionary Note on Forward-Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. These statements may be i

  3. Slide 3: Role of Infections in Triggering Fibromyalgia or Chronic fatigue (CFS)-Like Illnesses

    Role of Infections in Triggering Fibromyalgia or Chronic fatigue (CFS)-Like Illnesses CNS PORTFOLIO • Symptoms of Long COVID, like multi-site pain, fatigue and insomnia, are the hallmarks of chronic pain syndromes like fibromyalgia and chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). • E

  4. Slide 4: Rate of Central Sensitization in Long COVID and Comparability of Symptom Severity

    Rate of Central Sensitization (CS) in Long COVID and Comparability of Symptom Severity to CFS/ME and Fibromyalgia CNS PORTFOLIO ~70% Prevalence of CS in Long COVID patients1 Comparable symptom severity in Long COVID, CFS/ME and Fibromyalgia patients2 70% of Long COVID 30% Recent survey2 found partic

  5. Slide 5: Fibromyalgia-Type Long COVID

    Fibromyalgia-Type Long COVID CNS PORTFOLIO • Long COVID is a heterogeneous condition that displays elements of nociplastic pain in many individuals, who experience otherwise unexplained symptoms1-2 Fatigue Nociceptive Neuropathic pain pain Memory Multisite issues pain Sleep disturbances Nociplastic

  6. Slide 6: TNX-102 SL Cyclobenzaprine (Protectic)

    Fibromyalgia TNX-102 SL* Status: Mid-Phase 3 Cyclobenzaprine (Protectic®) • One positive Phase 3 study (RELIEF) completed • Second Phase 3 study (RALLY) missed primary endpoint Pipeline in a Product • Confirmatory Phase 3 study (RESILIENT) is currently enrolling A unique, sublingual formulation of c

  7. Slide 7: Phase 2 Long COVID Study Design (PREVAIL)

    Phase 2 Long COVID Study Design (PREVAIL) CNS PORTFOLIO Study characteristics: • Randomized, double-blind, placebo-controlled study of TNX-102 SL in fibromyalgia-type Long COVID • U.S. sites only, expected to enroll approximately 470 patients • One unblinded interim analysis based on 50% of randomiz

  8. Slide 8: Thank You

    THANK YOU © 2023 Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding — BIO and Solve M.E. Virtual Event (February 2023) on 6ix